SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis

[1] Bubba L(2021)Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March–June 2020 J Glob Health 11 05014-134

[2] Simmonds P(2021)Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis J Hosp Infect 108 120-8

[3] Fischer TK(2021)The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19 BMC Immunol 22 14-544

[4] Harvala H(2020)Prevalence of asymptomatic COVID-19 infection using a seroepidemiological survey Epidemiol Infect 148 3-1975

[5] Galanis P(2021)Clinical manifestation and disease progression in COVID-19 infection J Chin Med Assoc JCMA 84 535-473

[6] Vraka I(2020)Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study Lancet 396 1969-10

[7] Fragkou D(2021)Understanding the challenges and uncertainties of seroprevalence studies for SARS-CoV-2 Int J Environ Res Public Health 93 128-978

[8] Bilali A(2021)Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management Scand J Immunol 12 467-6110

[9] Kaitelidou D(2021)Antibody responses in COVID-19: a review Front Immunol 31 1-442

[10] Qin X(2021)Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation J Clin Microbiol 22 974-296

[1] Bubba L(2021)Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March–June 2020 J Glob Health 11 05014-134

[2] Simmonds P(2021)Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis J Hosp Infect 108 120-8

[3] Fischer TK(2021)The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19 BMC Immunol 22 14-544

[4] Harvala H(2020)Prevalence of asymptomatic COVID-19 infection using a seroepidemiological survey Epidemiol Infect 148 3-1975

[5] Galanis P(2021)Clinical manifestation and disease progression in COVID-19 infection J Chin Med Assoc JCMA 84 535-473

[6] Vraka I(2020)Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study Lancet 396 1969-10

[7] Fragkou D(2021)Understanding the challenges and uncertainties of seroprevalence studies for SARS-CoV-2 Int J Environ Res Public Health 93 128-978

[8] Bilali A(2021)Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management Scand J Immunol 12 467-6110

[9] Kaitelidou D(2021)Antibody responses in COVID-19: a review Front Immunol 31 1-442

[10] Qin X(2021)Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation J Clin Microbiol 22 974-296